• • 

    

    Charles Geyer, MD

    Peer

  7

  

  RestartResume

  RestartResume

  Improving Outcomes in HER2+ Early Breast Cancer

• • 

    

    Omid Hamid, MD

    Peer

  • 

    

    Do-Youn Oh, MD, PhD

    Peer

  10

  

  RestartResume

  RestartResume

  Biliary Tract Carcinoma: Are We at the Point of Change?

• • 

    

    Mark A. Socinski, MD

    Peer

  • 

    

    Jyoti Patel, MD

    Peer

  • 

    

    Benjamin Levy, MD

    Peer

  6

  

  RestartResume

  RestartResume

  Practical Considerations on the Use of Immune Checkpoint Inhibitors & Chemoth...

• • 

    

    Mitesh J. Borad, MD

    Peer

  • 

    

    Milind Javel, MD

    Peer

  8

  

  RestartResume

  RestartResume

  Rethinking Approaches to Biliary Tract Carcinoma

• • 

    

    Christine Bestvina, MD

    Peer

  1

  

  RestartResume

  RestartResume

  Getting Ahead of Recurrence in NSCLC

• • 

    

    Alfredo L. Falcone, MD

    Peer

  • 

    

    Sebastian Stintzing, MD

    Peer

  • 

    

    Tianshu Liu, MD

    Peer

  3

  

  RestartResume

  RestartResume

  Considerações Clínicas na Sequenciação do Tratamento do CCRM

Featured

• • 

    

    Scott Kopetz, MD, PhD, FACP

    Peer

  • 

    

    Alberto Sobrero, MD

    Peer

  • 

    

    Rui-Hua Xu, MD

    Peer

  19

  

  RestartResume

  RestartResume

  Improving Clinical Practice in Management of mCRC: A Focus on Tumor Sidedness

• • 

    

    Timothy A. McCarthy, MD

    Peer

  14

  

  RestartResume

  RestartResume

  Precision Oncology: Incorporating Next Generation Sequencing (NGS) in NSCLC

• • 

    

    Edward S. Kim, MD

    Peer

  3

  

  RestartResume

  RestartResume

  The Value of Multidisciplinary Teams in NSCLC Care Plans

• 4

  

  RestartResume

  RestartResume

  Best Practices for Existing Epidermal Growth Factor Receptor (EGFR) Inhibitor...

• • 

    

    Athanassios Argiris, MD, PhD, FACP

    Peer

  2

  

  RestartResume

  RestartResume

  Key Developments within Head & Neck Cancer
• 3

  

  RestartResume

  RestartResume

  Novel Therapies for Head & Neck Cancer

• • 

    

    Athanassios Argiris, MD, PhD, FACP

    Peer

  2

  

  RestartResume

  RestartResume

  Role of Immunotherapy in Head & Neck Cancer
• 4

  

  RestartResume

  RestartResume

  Head and Neck Physician Resources

• • 

    

    Makoto Tahara

    Peer

  6

  

  RestartResume

  RestartResume

  Patient Case Study: Role of Cetuximab in treatment of SCC Head and Neck Cance...
• 4

  

  RestartResume

  RestartResume

  Current Updates on Squamous Cell Cancer of the Head and Neck (SCCHN)
• 10

  

  RestartResume

  RestartResume

  Interview with Makoto Tahara, MD, PhD | Japan